Latest news with #HelmyEltoukhy
Yahoo
4 days ago
- Business
- Yahoo
Chris Wilder out as Sheffield United's US owners make managerial change
SHEFFIELD, England (AP) — Sheffield United parted ways with manager Chris Wilder on Wednesday after failing to secure a return to the Premier League. The club, which came under American ownership in late December, immediately installed Ruben Selles as Wilder's replacement. Advertisement Sheffield United lost to Sunderland in the Championship playoff final at Wembley Stadium last month to miss out on promotion. Wilder was in his second spell at the Yorkshire club after leading it to promotion in his first stint from 2016-21. 'A Blade through and through, the legacy Chris and his staff have created here will never be forgotten,' Sheffield United said in a statement. U.S.-based COH Sports completed the purchase of Sheffield United in late December. The group is led by Steven Rosen and Helmy Eltoukhy, who became the club's co-chairmen. ___ AP soccer: The Associated Press
The Guardian
12-06-2025
- Business
- The Guardian
Chris Wilder's future as Sheffield United manager in doubt before board meeting
Chris Wilder's future as Sheffield United manager is in doubt, with the club's American owners set to discuss his position at a board meeting. It is thought the recruitment strategy has been a significant factor in pushing Wilder's future towards a crossroads. The US-based consortium COH Sports, led by Steven Rosen and Helmy Eltoukhy, completed a takeover last December. The 57-year-old, in his second spell in charge of his boyhood club, led United to the Championship playoff final last month, which they lost to Sunderland, after missing out on automatic promotion. United are keen to press ahead with more 'data-driven' recruitment, which includes the use of artificial intelligence. This week United signed the Nigerian winger Ehije Ukaki from the Bulgarian club Botev Plovdiv, a move made by the winger Christian Nwachukwu, 19, in January. In the same window United signed Jefferson Cáceres, 22, from the Peruvian club FBC Melgar but neither Nwachukwu nor Caceres has made a first-team appearance. The Blades are one of several Championship clubs searching for a manager, with Middlesbrough, Queens Park Rangers and Bristol City also seeking to fill vacancies. Sign up to Football Daily Kick off your evenings with the Guardian's take on the world of football after newsletter promotion On Wednesday Hull City appointed Sergej Jakirovic as their head coach on a two-year contract, and this month West Brom appointed the former Tottenham coach Ryan Mason on a three-year contract.
Telegraph
12-06-2025
- Business
- Telegraph
New Sheffield United owners expected to sack Chris Wilder
Chris Wilder's future as Sheffield United manager is in doubt after the club's failure to seal a return to the Premier League. Wilder could be sacked later on Thursday by United's new owners, just under three weeks since the Championship play-off final defeat by Sunderland at Wembley. The 57-year-old's team was in contention for promotion for the majority of last season, despite a two-point deduction, but is expected to pay the price after falling short in his promotion bid. Senior officials are believed to be preparing for a recruitment meeting today. It will be the second time Wilder has been sacked by his boyhood club, following his previous dismissal in March 2021. He returned to the club in December 2023 and signed a new contract last season which would have run to 2028. United's new owners, American-based consortium COH Sports, are keen to make a new appointment before pre-season. The consortium, led by businessmen Steven Rosen and Helmy Eltoukhy, completed their takeover at Bramall Lane in December last year, when the team were top of the Championship. After the defeat by Sunderland last month, Wilder said: 'We've had the taste of Premier League, we know what a great experience it is and the experience that they'll have next season. 'It's going to take quite a while to get over this and we're going to have to suffer and go through the pain.' United are the latest Championship club to start searching for a new manager, joining Bristol City, Middlesbrough and Queens Park Rangers.
Business Wire
02-06-2025
- Business
- Business Wire
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the results of the Phase III SERENA-6 trial - sponsored by AstraZeneca - demonstrate the clinical value of the Guardant360® CDx test in a circulating tumor DNA-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of radiological disease progression in breast cancer. Study results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and were published in The New England Journal of Medicine. SERENA-6 is the first global, double-blind, registrational Phase III trial to use a ctDNA-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before disease progression is detected in imaging scans. The novel trial design used ctDNA monitoring with the Guardant360 liquid biopsy test at the time of routine tumor scans to identify patients for early signs of endocrine resistance and the emergence of ESR1 mutations. 'SERENA-6 is a landmark study that is creating a new paradigm using liquid biopsy to enable a switch to a new treatment as soon as you see the cancer showing signs of resistance,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'This use of the Guardant360 CDx test highlights how we are pushing the boundaries of what can be done with liquid biopsy in characterizing disease and potential drug efficacy, providing insights that could potentially change clinical practice and improve outcomes in patients with advanced breast cancer.' Following detection of an ESR1 mutation without radiological disease progression, the endocrine therapy of patients was switched to AstraZeneca's camizestrant from ongoing treatment with an aromatase inhibitor (AI), while continuing combination with the same cyclin-dependent kinase (CDK) 4/6 inhibitor. The trial demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors had an emergent ESR1 mutation as detected by Guardant360 CDx. About Guardant360 CDx The first FDA-approved blood test for complete genomic testing, Guardant360 CDx is approved as a companion diagnostic fur multiple therapies in non-small cell lung cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives. For more information, visit the Guardant360 CDx website. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Business Wire
31-05-2025
- Health
- Business Wire
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147) involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting. Results demonstrated that circulating tumor DNA detected in the bloodstream after cancer surgery and prior to the start of adjuvant therapy, using the Guardant Reveal test, is a strong predictor of the risk of disease recurrence and poorer survival, and suggest the potential for ctDNA testing to improve decision-making at a critical time point for post-operative chemotherapy. Specifically: Among patients with post-surgical ctDNA detected, 62.6% had the cancer return within 3 years, despite having had adjuvant chemotherapy, while only 15.4% of patients with undetectable ctDNA recurred in the same period. The level of ctDNA, or tumor fraction, showed promise in identifying individuals who are less likely to clear residual disease with adjuvant treatment. 'Thirty percent of patients with stage III colon cancer will relapse after surgery, despite having standard adjuvant chemotherapy,' said Frank Sinicrope, MD, professor of oncology and medicine at Mayo Clinic and principal investigator for the study. 'In this study, we demonstrate that analysis of postsurgical ctDNA can improve the prediction of disease recurrence over standard staging criteria, which may help guide patient management and follow-up. These data further support the routine use of ctDNA in management of stage III colon cancer patients.' 'With the Guardant Reveal test, a simple blood draw can be used to identify colorectal cancer patients who have molecular residual disease and are most likely to benefit from adjuvant therapy,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'This large study confirms the test's ability to identify high risk of cancer returning and support oncologists in making more informed therapeutic decisions to help improve patient outcomes.' The full abstract for the presentation can be found on the ASCO website. About Guardant Reveal Guardant Reveal, which runs on the Guardant Infinity™ smart liquid biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA, a marker of minimal residual disease, to predict cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy. The test is covered by Medicare for patients with colorectal cancer in the early post-surgical setting and for surveillance testing to monitor for disease recurrence after curative intent treatment. About Molecular Residual Disease Molecular residual disease refers to a subclinical measure of cancer burden that remains during and following treatment. A patient's MRD status is a reliable indicator of clinical outcome and response to therapy and can be used for risk stratification and to guide treatment options when used in conjunction with other clinical data. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
